Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD
Conditions
Interventions
Daratumumab 16 mg/kg (Part 1)
Daratumumab 8 mg/kg (Part 1)
+4 more
Locations
23
United States
Duarte, California, United States
Los Angeles, California, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Louisville, Kentucky, United States
Detroit, Michigan, United States
Start Date
September 27, 2013
Primary Completion Date
January 9, 2015
Completion Date
May 30, 2017
Last Updated
June 25, 2018
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06383143
NCT06057402
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions